Loading...

James Breitenbucher, PhD

TitleAdjunct Professor
InstitutionUniversity of California San Francisco
DepartmentInstitute for Neurodegenerative Diseases
Address675 Nelson Rising Lane
San Francisco CA 94158
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Rech JC, Bhattacharya A, Branstetter BJ, Love CJ, Leenaerts JE, Cooymans LP, Eckert WA, Ao H, Wang Q, Chaplan SR, Wickenden AD, Lebsack AD, Breitenbucher JG. The discovery and preclinical characterization of 6-chloro-N-(2-(4,4-difluoropiperidin-1-yl)-2-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinoline-5-carboxamide based P2X7 antagonists. Bioorg Med Chem Lett. 2016 10 01; 26(19):4781-4784. PMID: 27595421.
      View in: PubMed
    2. Keith JM, Tichenor MS, Apodaca RL, Xiao W, Jones WM, Seierstad M, Pierce JM, Palmer JA, Webb M, Karbarz MJ, Scott BP, Wilson SJ, Wennerholm ML, Rizzolio M, Rynberg R, Chaplan SR, Breitenbucher JG. The SAR of brain penetration for a series of heteroaryl urea FAAH inhibitors. Bioorg Med Chem Lett. 2016 07 01; 26(13):3109-3114. PMID: 27189675.
      View in: PubMed
    3. Keith JM, Jones WM, Tichenor M, Liu J, Seierstad M, Palmer JA, Webb M, Karbarz M, Scott BP, Wilson SJ, Luo L, Wennerholm ML, Chang L, Rizzolio M, Rynberg R, Chaplan SR, Breitenbucher JG. Preclinical Characterization of the FAAH Inhibitor JNJ-42165279. ACS Med Chem Lett. 2015 Dec 10; 6(12):1204-8. PMID: 26713105; PMCID: PMC4677372 [Available on 12/10/16].
    4. Keith JM, Hawryluk N, Apodaca RL, Chambers A, Pierce JM, Seierstad M, Palmer JA, Webb M, Karbarz MJ, Scott BP, Wilson SJ, Luo L, Wennerholm ML, Chang L, Rizzolio M, Chaplan SR, Breitenbucher JG. 1-Aryl-2-((6-aryl)pyrimidin-4-yl)amino)ethanols as competitive inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett. 2014 Mar 01; 24(5):1280-4. PMID: 24513048.
      View in: PubMed
    5. Keith JM, Jones WM, Pierce JM, Seierstad M, Palmer JA, Webb M, Karbarz MJ, Scott BP, Wilson SJ, Luo L, Wennerholm ML, Chang L, Brown SM, Rizzolio M, Rynberg R, Chaplan SR, Breitenbucher JG. Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett. 2014 Feb 01; 24(3):737-41. PMID: 24433863.
      View in: PubMed
    6. Gomez L, Breitenbucher JG. PDE2 inhibition: potential for the treatment of cognitive disorders. Bioorg Med Chem Lett. 2013 Dec 15; 23(24):6522-7. PMID: 24189054.
      View in: PubMed
    7. Tichenor MS, Keith JM, Jones WM, Pierce JM, Merit J, Hawryluk N, Seierstad M, Palmer JA, Webb M, Karbarz MJ, Wilson SJ, Wennerholm ML, Woestenborghs F, Beerens D, Luo L, Brown SM, Boeck MD, Chaplan SR, Breitenbucher JG. Heteroaryl urea inhibitors of fatty acid amide hydrolase: structure-mutagenicity relationships for arylamine metabolites. Bioorg Med Chem Lett. 2012 Dec 15; 22(24):7357-62. PMID: 23141911.
      View in: PubMed
    8. Keith JM, Apodaca R, Tichenor M, Xiao W, Jones W, Pierce J, Seierstad M, Palmer J, Webb M, Karbarz M, Scott B, Wilson S, Luo L, Wennerholm M, Chang L, Brown S, Rizzolio M, Rynberg R, Chaplan S, Breitenbucher JG. Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and Primate. ACS Med Chem Lett. 2012 Oct 11; 3(10):823-7. PMID: 24900385; PMCID: PMC4025847.
    9. McClure KJ, Maher M, Wu N, Chaplan SR, Eckert WA, Lee DH, Wickenden AD, Hermann M, Allison B, Hawryluk N, Breitenbucher JG, Grice CA. Discovery of a novel series of selective HCN1 blockers. Bioorg Med Chem Lett. 2011 Sep 15; 21(18):5197-201. PMID: 21824780.
      View in: PubMed
    10. Maher MP, Bhattacharya A, Ao H, Swanson N, Wu NT, Freedman J, Kansagara M, Scott B, Li DH, Eckert WA, Liu Y, Sepassi K, Rizzolio M, Fitzgerald A, Liu J, Branstetter BJ, Rech JC, Lebsack AD, Breitenbucher JG, Wickenden AD, Chaplan SR. Characterization of 2-(2,6-dichloro-benzyl)-thiazolo[5,4-d]pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine (JNJ-39729209) as a novel TRPV1 antagonist. Eur J Pharmacol. 2011 Aug 01; 663(1-3):40-50. PMID: 21575625.
      View in: PubMed
    11. Mapes CM, Mani NS, Deng X, Pandit CR, McClure KJ, Pippel MC, Sehon CA, Gomez L, Shinde S, Breitenbucher JG, Jones TK. Practical and scalable synthesis of a selective CCK1 receptor antagonist. J Org Chem. 2010 Nov 19; 75(22):7950-3. PMID: 20977279.
      View in: PubMed
    12. Hawryluk NA, Merit JE, Lebsack AD, Branstetter BJ, Hack MD, Swanson N, Ao H, Maher MP, Bhattacharya A, Wang Q, Freedman JM, Scott BP, Wickenden AD, Chaplan SR, Breitenbucher JG. Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrimido-[4,5-d]azepines as novel TRPV1 antagonists. Bioorg Med Chem Lett. 2010 Dec 01; 20(23):7137-41. PMID: 20947352.
      View in: PubMed
    13. Lebsack AD, Rech JC, Branstetter BJ, Hawryluk NA, Merit JE, Allison B, Rynberg R, Buma J, Rizzolio M, Swanson N, Ao H, Maher MP, Herrmann M, Freedman J, Scott BP, Luo L, Bhattacharya A, Wang Q, Chaplan SR, Wickenden AD, Breitenbucher JG. 1,2-diamino-ethane-substituted-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepines as TRPV1 antagonists with improved properties. Bioorg Med Chem Lett. 2010 Dec 01; 20(23):7142-6. PMID: 20932750.
      View in: PubMed
    14. Karbarz MJ, Luo L, Chang L, Tham CS, Palmer JA, Wilson SJ, Wennerholm ML, Brown SM, Scott BP, Apodaca RL, Keith JM, Wu J, Breitenbucher JG, Chaplan SR, Webb M. Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase. Anesth Analg. 2009 Jan; 108(1):316-29. PMID: 19095868.
      View in: PubMed
    15. Seierstad M, Breitenbucher JG. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008 Dec 11; 51(23):7327-43. PMID: 18983142.
      View in: PubMed
    16. Keith JM, Apodaca R, Xiao W, Seierstad M, Pattabiraman K, Wu J, Webb M, Karbarz MJ, Brown S, Wilson S, Scott B, Tham CS, Luo L, Palmer J, Wennerholm M, Chaplan S, Breitenbucher JG. Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett. 2008 Sep 01; 18(17):4838-43. PMID: 18693015.
      View in: PubMed
    17. Barrett TD, Yan W, Freedman JM, Lagaud GJ, Breitenbucher JG, Shankley NP. Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction. Br J Pharmacol. 2008 Apr; 153(8):1650-8. PMID: 18297100; PMCID: PMC2438255.
    18. Timmons A, Seierstad M, Apodaca R, Epperson M, Pippel D, Brown S, Chang L, Scott B, Webb M, Chaplan SR, Breitenbucher JG. Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett. 2008 Mar 15; 18(6):2109-13. PMID: 18289847.
      View in: PubMed
    19. Maher M, Ao H, Banke T, Nasser N, Wu NT, Breitenbucher JG, Chaplan SR, Wickenden AD. Activation of TRPA1 by farnesyl thiosalicylic acid. Mol Pharmacol. 2008 Apr; 73(4):1225-34. PMID: 18171730.
      View in: PubMed
    20. Neff DK, Lee-Dutra A, Blevitt JM, Axe FU, Hack MD, Buma JC, Rynberg R, Brunmark A, Karlsson L, Breitenbucher JG. 2-Aryl benzimidazoles featuring alkyl-linked pendant alcohols and amines as inhibitors of checkpoint kinase Chk2. Bioorg Med Chem Lett. 2007 Dec 01; 17(23):6467-71. PMID: 17937984.
      View in: PubMed
    21. Gomez L, Hack MD, McClure K, Sehon C, Huang L, Morton M, Li L, Barrett TD, Shankley N, Breitenbucher JG. SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 01; 17(23):6493-8. PMID: 17933530.
      View in: PubMed
    22. Morton MF, Barrett TD, Yan W, Freedman JM, Lagaud G, Prendergast CE, Moreno V, Pyati J, Figueroa K, Li L, Wu X, Rizzolio M, Breitenbucher JG, McClure K, Shankley NP. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide. J Pharmacol Exp Ther. 2007 Nov; 323(2):562-9. PMID: 17684117.
      View in: PubMed
    23. Romero FA, Du W, Hwang I, Rayl TJ, Kimball FS, Leung D, Hoover HS, Apodaca RL, Breitenbucher JG, Cravatt BF, Boger DL. Potent and selective alpha-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase. J Med Chem. 2007 Mar 08; 50(5):1058-68. PMID: 17279740; PMCID: PMC2531193.
    24. Lee-Dutra A, Arienti KL, Buzard DJ, Hack MD, Khatuya H, Desai PJ, Nguyen S, Thurmond RL, Karlsson L, Edwards JP, Breitenbucher JG. Identification of 2-arylbenzimidazoles as potent human histamine H4 receptor ligands. Bioorg Med Chem Lett. 2006 Dec 01; 16(23):6043-8. PMID: 16990005.
      View in: PubMed
    25. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, Breitenbucher JG, Chaplan SR, Webb M. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol. 2006 May; 148(1):102-13. PMID: 16501580; PMCID: PMC1617043.
    26. McClure KJ, Huang L, Arienti KL, Axe FU, Brunmark A, Blevitt J, Breitenbucher JG. Novel non-benzimidazole chk2 kinase inhibitors. Bioorg Med Chem Lett. 2006 Apr 01; 16(7):1924-8. PMID: 16442290.
      View in: PubMed
    27. McClure K, Hack M, Huang L, Sehon C, Morton M, Li L, Barrett TD, Shankley N, Breitenbucher JG. Pyrazole CCK(1) receptor antagonists. Part 1: Solution-phase library synthesis and determination of Free-Wilson additivity. Bioorg Med Chem Lett. 2006 Jan 01; 16(1):72-6. PMID: 16236513.
      View in: PubMed
    28. Sehon C, McClure K, Hack M, Morton M, Gomez L, Li L, Barrett TD, Shankley N, Breitenbucher JG. Pyrazole CCK(1) receptor antagonists. Part 2: SAR studies by solid-phase library synthesis and determination of Free-Wilson additivity. Bioorg Med Chem Lett. 2006 Jan 01; 16(1):77-80. PMID: 16236506.
      View in: PubMed
    29. Arienti KL, Brunmark A, Axe FU, McClure K, Lee A, Blevitt J, Neff DK, Huang L, Crawford S, Pandit CR, Karlsson L, Breitenbucher JG. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24; 48(6):1873-85. PMID: 15771432.
      View in: PubMed
    30. Swanson DM, Dubin AE, Shah C, Nasser N, Chang L, Dax SL, Jetter M, Breitenbucher JG, Liu C, Mazur C, Lord B, Gonzales L, Hoey K, Rizzolio M, Bogenstaetter M, Codd EE, Lee DH, Zhang SP, Chaplan SR, Carruthers NI. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J Med Chem. 2005 Mar 24; 48(6):1857-72. PMID: 15771431.
      View in: PubMed
    31. Lee A, Breitenbucher JG. The impact of combinatorial chemistry on drug discovery. Curr Opin Drug Discov Devel. 2003 Jul; 6(4):494-508. PMID: 12951813.
      View in: PubMed
    32. Chai W, Breitenbucher JG, Kwok A, Li X, Wong V, Carruthers NI, Lovenberg TW, Mazur C, Wilson SJ, Axe FU, Jones TK. Non-imidazole heterocyclic histamine H3 receptor antagonists. Bioorg Med Chem Lett. 2003 May 19; 13(10):1767-70. PMID: 12729661.
      View in: PubMed
    33. Shah C, McAtee L, Breitenbucher JG, Rudolph D, Li X, Lovenberg TW, Mazur C, Wilson SJ, Carruthers NI. Novel human histamine H(3) receptor antagonists. Bioorg Med Chem Lett. 2002 Nov 18; 12(22):3309-12. PMID: 12392739.
      View in: PubMed
    34. Mackman RL, Hui HC, Breitenbucher JG, Katz BA, Luong C, Martelli A, McGee D, Radika K, Sendzik M, Spencer JR, Sprengeler PA, Tario J, Verner E, Wang J. 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors. Bioorg Med Chem Lett. 2002 Aug 05; 12(15):2019-22. PMID: 12113832.
      View in: PubMed
    35. Breitenbucher JG, Arienti KL, McClure KJ. Scope and limitations of solid-supported liquid-liquid extraction for the high-throughput purification of compound libraries. J Comb Chem. 2001 Nov-Dec; 3(6):528-33. PMID: 11703147.
      View in: PubMed